• LAST PRICE
    0.6050
  • TODAY'S CHANGE (%)
    Trending Up0.0050 (0.8333%)
  • Bid / Lots
    0.5600/ 1
  • Ask / Lots
    0.6070/ 1
  • Open / Previous Close
    0.6070 / 0.6000
  • Day Range
    Low 0.6050
    High 0.6070
  • 52 Week Range
    Low 0.5200
    High 3.1300
  • Volume
    368
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.6
TimeVolumeUNCY
09:36 ET2830.605
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesUNCY
Unicycive Therapeutics Inc
9.0M
-0.6x
---
United StatesCWBR
CohBar Inc
8.6M
-0.6x
---
United StatesGLMD
Galmed Pharmaceuticals Ltd
8.3M
-0.3x
---
United StatesPHIO
Phio Pharmaceuticals Corp
8.1M
-0.6x
---
United StatesLIXT
Lixte Biotechnology Holdings Inc
9.8M
-1.3x
---
United StatesPALI
Palisade Bio Inc
8.0M
0.3x
---
As of 2022-10-04

Company Information

Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD), and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively. CKD is the gradual loss of kidney function, which leads to electrolyte imbalances, fluid build-up, anemia, bone disease, and heart disease. Hyperphosphatemia is an electrolyte disorder in which untreated elevated phosphate levels in the blood lead to cardiovascular complications and vascular calcification.

Contact Information

Headquarters
4300 El Camino Real, Suite 210LOS ALTOS, CA, United States 94022
Phone
650-384-0642
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Shalabh Gupta
Chief Financial Officer
John Townsend
Executive Vice President - Pharmaceutical and Business Operations
Pramod Gupta
Independent Director
Sandeep Laumas
Independent Director
John Ryan

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.0M
Revenue (TTM)
$0.00
Shares Outstanding
15.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.03
Book Value
$1.10
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.